OpGen Subsidiary Curetis and Annar Enter into Unyvero Distribution Partnership for Colombia
January 05 2021 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company
harnessing the power of molecular diagnostics and bioinformatics to
help combat infectious disease, announced today that its subsidiary
Curetis GmbH has entered into a distribution agreement with Annar
Health Technologies (“Annar”) for Colombia. Annar, headquartered in
Bogotá, is Colombia’s leading diagnostics distributor that is
already working with numerous renowned global IVD manufacturers.
Under the distribution agreement, Annar has the
exclusive rights to commercialize the Curetis Unyvero A50
instrument system and its full suite of Unyvero infectious disease
diagnostic application cartridges in Colombia. The distribution
agreement has an initial term of three years and can be extended in
one-year increments. In return, Annar has committed to significant
minimum purchases of Unyvero instruments and application cartridges
over the initial three year term, amounting to a total of at least
10 Unyvero systems plus significant numbers of Unyvero cartridges.
Annar is responsible for product registration which is expected to
be obtained by the second half of 2021 and has committed to
significantly invest in the market introduction of the Unyvero
product line in Colombia.
“With a significant number of hospitalized
patients suffering from healthcare-associated infections in
Colombia, we believe that a rapid and comprehensive detection of
the pathogens and their antibiotic resistance markers with Unyvero
will help to improve outcomes for patients with severe infections
while supporting the antibiotic stewardship efforts that are high
on the agenda of our healthcare providers,” said Michael Himmel,
CEO of Annar Health Technologies.
“We are very pleased to work with Annar as a
highly committed partner in making Unyvero widely available in
Colombia,” said Oliver Schacht, PhD, CEO of OpGen. “This
partnership strengthens our commercial presence in the Latin
American region and is in alignment with our core commercialization
strategy to expand our global presence as industry leaders in the
molecular diagnostics and bioinformatics space. We anticipate
working closely with Annar and the team over the coming months and
anticipate the opportunity to explore potential expansion into
additional Latin American countries in the years ahead.”
About OpGen,
Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries Curetis GmbH and Ares Genetics GmbH, we are
developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements by
OpGen
This press release includes statements regarding
OpGen’s subsidiary Curetis’ entry into of an exclusive distribution
agreement for its Unyvero products in Colombia. These statements
and other statements regarding OpGen’s Unyvero products, their
commercialization and launch, future plans and goals constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, the rate of adoption of our
products and services by hospitals and other healthcare providers,
the fact that we may not effectively use proceeds from recent
financings, including our November 2020 private placement, the
realization of expected benefits of our business combination
transaction with Curetis GmbH, the success of our commercialization
efforts, the impact of COVID-19 on the Company’s operations,
financial results, and commercialization efforts as well as on
capital markets and general economic conditions, the effect on our
business of existing and new regulatory requirements, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen Contact:Oliver
SchachtCEOInvestorRelations@opgen.com
Press Contact:Matthew
BretziusFischTank Marketing and PRmatt@fischtankpr.com
Investor Contact:Megan
PaulEdison Groupmpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024